Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

GSK plc

Tracked across 42 events · 1618 articles · First seen Feb 10, 2025 · Last active Sep 22, 2026

Sentiment
15
Attention
8
Events
42
Relationships
50
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 90
Business
Impact: GSK plc>>> is being acquired by GSK plc>>> for $10.6 billion, representing a 40% premium to its last closing price. This acquisition validates GSK plc>>>'s innovative work in developing targeted cancer therapies, particularly for lung cancer, and provides its shareholders with significant value.
Jun 09, 2026 · 56 articles
6 70
Tech
Impact: As a developer and funder of bepirovirsen, GSK plc stands to benefit significantly from the drug's potential approval and market success, enhancing its reputation and financial outlook in the pharmaceutical industry.
May 28, 2026 · 8 articles
4 30
Regulatory
Impact: GSK received FDA approval for its first lung cancer drug Jideytro, enhancing its oncology portfolio and potentially driving future revenue growth.
Jul 22, 2026 · 6 articles
3 10
Business
Impact: GSK is restructuring its R&D operations, closing Stevenage and opening a new Cambridge site, aiming to cut costs by £1.9 billion and reinvest in R&D. The move is strategically positive but involves short-term costs and job changes.
Jul 28, 2026 · 6 articles
2 15
Business
GSK plc announced on September 15, 2026 that it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma from privately held clinical-stage biotechnology firm Chimagen Biosciences. The agreement…
Impact: GSK is the acquirer, paying up to $750 million for full global rights to Chimagen's trispecific TCE, expanding its multiple myeloma franchise alongside Blenrep and its broader oncology pipeline. The deal is strategically positive but financially small relative to GSK's scale, and its shares gained around 0.92 percent in overnight trading.
Sep 15, 2026 · 8 articles
6 20
Regulatory
Impact: GSK plc is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
4 50
Tech
Impact: GSK plc is the maker of the Zoster vaccine vaccine. The study, although funded by GSK plc, was independently designed and conducted, and its positive findings regarding dementia risk reduction could enhance the company's reputation and vaccine sales.
Jun 15, 2026 · 6 articles
4 70
Tech
A large observational study published in Annals of Internal Medicine found that older adults who received the Shingrix shingles vaccine after entering a skilled nursing facility had a 24% lower risk of being diagnosed with…
Impact: Manufacturer of Shingrix and funder of the study. Positive findings could enhance its vaccine franchise and revenue prospects.
Aug 25, 2026 · 7 articles
2 5
Regulatory
Chairs of nine European pharmaceutical companies published an open letter on their corporate websites on September 22, 2026, calling on the European Union and its member states to boost investment in the region's drug industry.…
Impact: A signatory of the open letter pressing the European Union for more medicine spending, faster trials and IP protection. Its participation underscores the sector's push for a more favorable European operating environment.
Sep 22, 2026 · 6 articles
2 -1
Business
Impact: GSK plc is under investigation by Monteverde & Associates PC regarding its sale to GSK plc, with shareholders expected to receive $124.00 per share in cash.
May 19, 2026 · 45 articles
8 50
Business
Impact: GSK plc has adopted a more aggressive M&A approach following recent CEO transitions, contributing to the overall increase in dealmaking.
May 01, 2026 · 6 articles
2 20
Business
Impact: GSK holds exclusive license to Utebzi outside certain Asian territories; its sales payments back the financing.
Jul 14, 2026 · 9 articles
4 -20
Business
Impact: GSK faces increased generic competition for its branded Advair Diskus, potentially eroding market share and revenue in the US.
Aug 31, 2026 · 7 articles
4 20
Regulatory
Impact: GSK plc benefits from the expanded label of the VENTANA MMR RxDx Panel as it identifies patients eligible for its Dostarlimab therapy, potentially increasing the drug's market reach.
Jun 11, 2026 · 6 articles
4 40
Business
Impact: Original developer supplying adjuvant; potential royalties if vaccine succeeds.
Jul 16, 2026 · 14 articles
6 -10
Domestic
Impact: Vaccine maker, similarly affected by potential unbundling, but no immediate change.
Aug 10, 2026 · 266 articles
8 20
Tech
Impact: GSK plc>>>'s drug Avodart is mentioned in a comparison study where GLP-1s were associated with lower rates of prostate cancer diagnoses.
Jun 02, 2026 · 45 articles
3 20
Business
Impact: GSK plc had an executive, Jeremy Pincus, recognized with an Ignite Leadership Award for driving enterprise-wide AI transformations within the company.
Jun 25, 2026 · 8 articles
2 30
Tech
Impact: GSK is a consortium member. The publication may inform its clinical development programs in ALS and FTD.
Aug 18, 2026 · 6 articles
7 20
Business
Impact: GSK plc>>> agreed to acquire GSK plc>>> for $10.6 billion, marking its largest deal in years and expanding its presence in cancer drug development.
May 20, 2026 · 72 articles
7 -20
Regulatory
Impact: GSK plc's flu vaccines face potential competition from mFLUSIVA.
Aug 05, 2026 · 105 articles
2 0
Business
Impact: GSK plc is a partner of Innoviva, from whom Innoviva receives royalties on sales of respiratory assets.
Jun 01, 2026 · 6 articles
3 -10
Business
Impact: GSK's RSV vaccine Arexvy faces increased competition from Moderna's mRESVIA in the EU market.
Jul 09, 2026 · 6 articles
7 80
Business
Impact: Soared 39% after GSK agreed to buy it for $10.6 billion.
Apr 20, 2026 · 344 articles
7 0
Business
Impact: GSK plc is AstraZeneca's main UK rival, which AstraZeneca overtook in size under Soriot. The merger would further widen the gap.
Aug 02, 2026 · 60 articles
4 50
Business
Impact: GSK plc's acquisition of Nuvalent Inc. is another example of big pharma M&A that supports biotech valuations.
Jul 06, 2026 · 25 articles
6 5
Business
Revolut founder and CEO Nik Storonsky confirmed on Thursday that the fintech firm is exploring a dual stock market listing on the Aquis Stock Exchange and the Nasdaq, in an interview with French newspaper Les…
Impact: GSK plc is referenced as a FTSE heavyweight that Revolut could outrank by valuation, illustrating the significance of the potential listing for the UK market.
Sep 17, 2026 · 7 articles
6 0
Business
Impact: GSK plc is mentioned as the former parent company from which Haleon was spun off in 2022, providing historical context to Haleon's current operations.
Jun 08, 2026 · 19 articles
1 0
Business
Impact: GSK plc is mentioned as a previous employer of Ian Marks, providing context for his experience but not directly affected by the event.
Aug 10, 2026 · 6 articles
8 -10
International
Impact: Pharmaceutical company, whose stock fell on higher oil prices and inflation concerns.
Jul 28, 2026 · 318 articles
+ 12 more events View on Dashboard
ERGEN INTELLIGENCE
Track GSK plc live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.